| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.5M | — | -22.4% |
| SG&A Expense | $1.1M | — | -25.6% |
| Operating Income | -$2.6M | — | +23.8% |
| Net Income | -$2.7M | — | +22.5% |
| EPS (Basic) | -$0.17 | — | +37.0% |
| EPS (Diluted) | -$0.17 | — | +37.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.0M | -35.2% | -64.2% |
| Current Assets | $4.9M | -29.2% | -60.5% |
| Total Assets | $5.6M | -26.4% | -54.7% |
| Current Liabilities | $1.4M | -1.4% | +75.7% |
| Total Liabilities | $1.4M | -1.4% | +75.7% |
| Stockholders' Equity | $4.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.1M | — | -9.4% |
| Investing Cash Flow | $147K | — | — |
| Financing Cash Flow | $701K | — | -90.1% |
| -63.9% |